Holen Sie sich die Stockscreener-App
521.83
1.33%
-7.07
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt VRTX?
Forum
Prognose
Aktiensplit
Vertex Pharmaceuticals Inc Aktie (VRTX) Neueste Nachrichten
Where does Vertex Pharmaceuticals (NASDAQ:VRTX) fit within the Healthcare stocks conversation? - Kalkine Media
Vertex Pharmaceuticals: Solid Growth But Valuation Still Requires Flawless Execution - Seeking Alpha
Vertex Pharma stock heads into the open after a 3.1 percent drop - AD HOC NEWS
Vertex Pharmaceuticals Inc Stock (VRTX) Moved Down by 3.06% on Sep 8: What Signal Does It Send? - TradingKey
Goldman Sachs Just Added Vertex Pharmaceuticals to Its Conviction List. Here's the Bull Case for the Big Biotech Stock - The Motley Fool
Vertex Pharmaceuticals (VRTX) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance
Why CRISPR Therapeutics Stock Rocked the Market Last Month - The Motley Fool
Vertex Pharmaceuticals stock edges lower as market digests strong Q2 figures and insider selling - AD HOC NEWS
Vertex shares fall as investors digest Crinetics acquisition and related financing plans - Quiver Quantitative
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know - Yahoo Finance
Could Nasdaq Focus Lift Attention on Vertex Pharmaceuticals (NASDAQ:VRTX)? - Kalkine Media
Vertex Pharmaceuticals stock steadies near a 52-week high - AD HOC NEWS
Why Vertex stock is sliding today - Wealth Awesome
Vertex Pharmaceuticals (VRTX) Stock Analysis: A Biotech Titan with 4.29% Upside and Robust Buy Ratings - DirectorsTalk Interviews
Vertex Pharma stock slips as revenue and EPS stay in view - AD HOC NEWS
Vertex makes some big people moves, completes its largest acquisition - The Boston Globe
Vertex Pharmaceuticals (VRTX) Q1 2026 Earnings Call Transcript - Fortune
Vertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now? - The Motley Fool
Here's How Much $100 Invested In Vertex Pharmaceuticals 20 Years Ago Would Be Worth Today - Benzinga
Chutes & Ladders—Invivyd's chairman adds CEO role ahead of COVID readout - Fierce Biotech
Is Vertex Pharmaceuticals (VRTX) Undervalued Following Casgevy’s FDA Label Expansion? - simplywall.st
Vertex Tops Citi’s Biotech Picks After Crinetics Deal Completion By Investing.com - Investing.com Canada
Fierce Biotech Layoff Tracker 2026: Novartis nixes Swiss site; TScan telegraphs 75% headcount drop - Fierce Biotech
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Vertex stock wins Overweight at Morgan Stanley (VRTX:NASDAQ) - Seeking Alpha
How Is Vertex Pharmaceuticals' Stock Performance Compared to Other Biotech Stocks? - Yahoo Finance
Why Is Vertex (VRTX) Up 14.4% Since Last Earnings Report? - Yahoo Finance
Vertex Pharmaceuticals stock hits all-time high at $555.84 By Investing.com - Investing.com Canada
Vertex Pharmaceuticals stock hits all-time high at $555.84 - Investing.com India
Vertex (VRTX) Stock Trades At A Premium On Earnings Yet Looks Fair On Broader Checks - Yahoo Finance
Vertex Pharmaceuticals (VRTX) Appoints Jonathan Poole as New Chi - GuruFocus
Crinetics Director Stephanie Okey Sells All Shares Following Vertex Pharmaceuticals Merger - Kalkine Media
Crinetics Director Wendell Wierenga Reports Stock Disposals Following Vertex Merger - Kalkine Media
Vertex buyout pays Crinetics (CRNX) insider in cash, but his options fared very differently - Stock Titan
Crinetics (NASDAQ: CRNX) director’s stock, options and RSUs all vest and turn to cash in Vertex buyout - Stock Titan
Crinetics (NASDAQ: CRNX) CCO awards vest, then are cashed out or wiped in $85-a-share Vertex merger - Stock Titan
Takeover hands Crinetics (CRNX) science chief an $85-a-share cash exit - Stock Titan
Vertex’s $85 deal cashes out Crinetics (NASDAQ: CRNX) awards - Stock Titan
Crinetics (CRNX) shareholders receive $85 per share as Vertex takeover closes - Stock Titan
Vertex (NASDAQ: VRTX) records new insider stock transaction - Stock Titan
Vertex Pharmaceuticals Incorporated Appoints Jonathan Poole as Executive Vice President, Effective January 1, 2027 - marketscreener.com
Vertex Pharmaceuticals (VRTX) Could Be 3% Undervalued If Its Pipeline Growth Holds - Yahoo Finance
Vertex Completes $10 Billion Crinetics Acquisition, Adding Rare Endocrine Growth Platform - Yahoo Finance
Vertex Completes $10 Billion Acquisition of Crinetics at $85 Per Share - Minichart
Vertex Names Jonathan Poole Finance Chief as Crinetics Buy Closes - marketscreener.com
Vertex Pharmaceuticals Closes Crinetics Pharmaceuticals Acquisition - marketscreener.com
Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team - Business Wire
Vertex (NASDAQ: VRTX) director gifts 6,000 shares - Stock Titan
Shareholder approval clears way for Crinetics (NASDAQ: CRNX) sale to Vertex - Stock Titan
Vertex (NASDAQ: VRTX) director to sell $663K in shares via charity - Stock Titan
If You Invested $100 In Vertex Pharmaceuticals Stock 20 Years Ago, You Would Have This Much Today - Benzinga
Vertex to Participate in Upcoming September Investor Conferences - Business Wire
Vertex Pharmaceuticals Up 15% in a Month: How to Play the Stock - Eastern Progress
Lupin Wins Ruling on Vertex Patents for Cystic Fibrosis Drug - Bloomberg Law News
Vertex Pharmaceuticals (VRTX) Stock Analysis: Strong Revenue Growth and Promising Drug Pipeline Propel Investor Interest - DirectorsTalk Interviews
Vertex Pharmaceuticals: A Biotech Cash Cow With Pipeline Upside? - The Globe and Mail
Uber, ServiceNow And A Health Care Stock On CNBC’s ‘Final Trades’ - Benzinga
Why Is Vertex Pharmaceuticals (NASDAQ:VRTX) Pipeline Value in Focus? - Kalkine Media
Vise Technologies Inc. Makes New Investment in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Trillium Asset Management LLC Acquires New Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
PCM Encore LLC Invests $1.06 Million in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
B. Metzler seel. Sohn & Co. AG Acquires Shares of 231,381 Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Bank of New York Mellon Corp Purchases Shares of 1,672,623 Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
1.23%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):